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Abstract
Background: Recent studies have demonstrated a direct involvement of B7-H1, PD-1 and FOXP3
molecules in the immune escape of cancer. B7-H1 is an inhibitory molecule that binds to PD-1 on
T lymphocytes, while FOXP3 is a marker for regulatory T cells (Tregs). We have previously
demonstrated the association of B7-H1-expressing T infiltrating lymphocytes (TIL) with high-risk
breast cancer patients while other studies reported the involvement of FOXP3+ Tregs as a bad
prognostic factor in breast tumors. Although the co-existence between the two types of cells has
been demonstrated in vitro and animal models, their relative infiltration and correlation with the
clinicopathological parameters of cancer patients have not been well studied. Therefore, we
investigated TIL-expressing the B7-H1, PD-1, and FOXP3 molecules, in the microenvironment of
human breast tumors and their possible association with the progression of the disease.
Methods: Using immunohistochemistry, tumor sections from 62 breast cancer patients were co-
stained for B7-H1, PD-1 and FOXP3 molecules and their expression was statistically correlated
with factors known to be involved in the progression of the disease.
Results: A co-existence of B7-H1+ T lymphocytes and FOXP3+ Tregs was evidenced by the highly
significant correlation of these molecules (P  < .0001) and their expression by different T
lymphocyte subsets was clearly demonstrated. Interestingly, concomitant presence of FOXP3+
Tregs, B7-H1+ and PD-1+ TIL synergistically correlated with high histological grade (III) (P < .001),
estrogen receptor negative status (P = .017), and the presence of severe lymphocytic infiltration (P
= .022).
Conclusion:  Accumulation of TIL-expressing such inhibitory molecules may deteriorate the
immunity of high-risk breast cancer patients and this should encourage vigorous combinatorial
immunotherapeutic approaches targeting Tregs and B7-H1/PD-1 molecules.
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Background
It is widely believed that dysfunction in the immune sys-
tem of cancer patients allows the tumor cells to escape a
process termed immunosurveillance [1-3]. A T lym-
phocytes inhibitory molecule named B7-H1 (also called
PD-L1) expressed by antigen presenting cells has been
shown to induce T lymphocyte anergy and/or apoptosis
after ligation to its T lymphocytes receptor PD-1 [4-7]. B7-
H1 has been shown to be directly involved in the protec-
tion of cancer cells from activated T lymphocytes [8].
Indeed, the expression of this molecule and its receptor
has been described in several malignancies [9-17] where a
strong link between its expression by the cancer cells and
the patient clinicopathological status has been demon-
strated in some of these malignancies [9,11,13,16]. We
have shown previously that B7-H1 (PD-L1) is expressed in
the tumor tissues of 50% of breast cancer patients and its
expression was significantly associated with some impor-
tant prognostic factors linked to high-risk patients [18].
Regulatory T cells (Tregs) are a subset of T lymphocytes that
regulate the immune response by suppressing the prolifer-
ation and cytokines production of effector T lymphocytes
[19,20]. Tregs are thus important for protecting our body
by suppressing auto-reactive T lymphocytes. FOXP3, a
forkhead/winged helix transcription factor was found to
be essential for the development and control of Tregs
[21,22]. It has been used recently as a biomarker and a
prognostic factor for malignant human tumor as reviewed
in [23]. A direct link between the presence of Tregs and pro-
gression of ovarian carcinoma has been demonstrated
where human tumor FOXP3+ Tregs were found to suppress
tumor specific immunity and contribute to reduced sur-
vival of these patients [24]. In breast cancer, an increase in
Tregs population both in peripheral blood and tumor tis-
sues was also reported [25] and a recent study demon-
strated a significant intratumoral infiltration of FOXP3+
Tregs in high-risk breast cancer patients and those at risk of
late relapse [26].
Compelling evidences indicate a key role for the involve-
ment of B7-H1 molecule in the development of Tregs.
Induction of adaptive CD4+CD25+ Tregs which develop in
the periphery from CD4+CD25- naïve T lymphocytes (in
contrast to natural Tregs formed in the thymus) could not
be formed in mice which are B7 -/- [27]. In addition, mice
vascular endothelial cells were able to induce
CD4+CD25+FOXP3+ Tregs only in the presence of B7-H1
[28]. Another study has demonstrated the involvement of
B7-H1 as an essential element for the induction of Tregs
after intra-tracheal delivery of an alloantigen [29]. Fur-
thermore, B7-H1 was found to affect the function of Tregs
in which its blockade decreased the inhibitory effect of
such cells [30] and blockade of B7-H1/PD-1 interactions
abrogated Tregs-mediated immunoregulation [31].
Although these studies have demonstrated the interaction
between B7-H1 molecule and Tregs in animal models their
co-existence in cancer patients was not evaluated. This is
the first study to investigate the correlation between
FOXP3+ Tregs  and TIL-expressing B7-H1 and PD-1 in
breast cancer patients. We have shown that their co-infil-
tration is strongly associated with high-risk prognostic fac-
tors and those T lymphocytes expressing FOXP3, B7-H1
and PD-1 molecules are of different T lymphocytes sub-
sets.
Methods
Patients and samples collection
This study was conducted in accordance with Helsinki
Declaration and all patients signed a consent form
approved by the Research Ethics Committee of King Faisal
Specialist Hospital and Research Center (KFSH&RC). The
study was approved by the Research Advisory Council
(RAC) of KFSH&RC (RAC# 2030 034).
Breast cancer specimens were collected from primary
tumors of 68 patients including the 44 patients reported
in our previous study [18] (median age 44 years) who
were seeking treatments and had to undergo surgery
(breast conservative surgery or total mastectomy) at
KFSH&RC from 2003 to 2006. From the selected patients,
6 patients were removed from the study as they had no
detectable TIL. Normal breast tissues were also obtained
from 2 healthy women undergoing a plastic surgery and
designated as BP. Upon excision of tissues by a surgeon,
an anatomical pathologist obtained sample of the tumor
tissue, denoted T, and an adjacent normal breast tissue
from the same breast having the tumor, denoted N. Tis-
sues from both T and N were processed as described
before [18]. Briefly, they were fixed in formalin and
embedded in paraffin for routine histopathological anal-
ysis while other piece was snap frozen in liquid nitrogen,
preserved at -80°C and sectioned using a cryostat.
Immunohistochemistry
Routine formalin-fixed, paraffin-embedded hospital tests
were evaluated by immunohistochemistry for Her/2neu,
Estrogen receptor, and progesterone receptor status as
described before [18] while immunohistochemistry stain-
ing of frozen tissue sections were carried out as follows:
(a) Single staining
B7-H1 and PD-1 detection were carried out as described
previously on fresh cryogenic sections with slight modifi-
cations [18,32] in which a very brief fixation in 2% para-
formaldehyde (Fisher scientific) in PBS at RT (4 minutes
for B7-H1 and 10 minutes for PD-1) was initially applied
to improve the morphology of section. Briefly, sections
were incubated for 15 minutes in 0.3% hydrogen perox-
ide solution and 0.1% sodium azide (Sigma, Saint Louis,BMC Cancer 2008, 8:57 http://www.biomedcentral.com/1471-2407/8/57
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MO, USA). Sections were blocked with 10% goat serum
(DAKO, Denmark) for 30 minutes followed by B7-H1
antibody (MIH1 clone, ebioscience, San Diego, CA, USA)
or PD-1 antibody (J116 clone, ebioscience,) diluted at
1:50 overnight. After washing, sections were stained for 30
minutes at RT, with Labeled Polymer (EnVision+) horse-
radish peroxidase (HRP) detection kit (DAKO). Colors
were developed using DAB (Novocastra, Newcastle upon
Tyne, UK) or AEC (Sigma) and sections were counter-
stained with instant hematoxylin (Shandon, Pittsburgh,
PA, USA).
(b) Double staining
Sections were washed in PBS, incubated with paraformal-
dehyde for 4 minutes and blocked in H2O2 and goat
serum as described above. The primary and secondary
antibodies were added as follows: For CD3/FOXP3, CD8/
FOXP3, CD8/PD-1 or CD8/B7-H1 double staining the 2
primary antibodies from two different species, mouse
anti-FOXP3 (236A/E7 clone, ebioscience) diluted at
1:100, mouse anti-B7-H1 (clone MIH1, ebioscience)
diluted at 1:25 or mouse anti-PD-1 antibody (J116 clone,
ebioscience) diluted at 1:50 were mixed with rabbit anti-
CD3 (Dako) at 1:50 dilution or rabbit anti-CD8 (Abcam,
Cambridge, UK) at 1:75 dilution, together in 10% human
AB serum (Cambrex) and incubated for 2 h at RT or over-
night at 4°C. Sections were washed 3 times in PBS and
incubated for 30 minutes at RT with a secondary anti-
body: swine anti-rabbit AP (Dako) diluted at 1:50 in a
ready-to-use polymer (Envision+, Dako) linked to HRP.
After washing 3 times with PBS, substrates were added
starting with fuschin red (Dako) followed by DAB (Novo-
castra). Slides were counterstained with instant hematox-
ylin (Shandon). FOXP3 and B7-H1 double staining were
carried out as described above except the primary antibod-
ies used were rabbit anti-FOXP3 (polyclonal, Abcam) at
1:500 dilution mixed with mouse anti-B7-H1 (clone
MIH1, ebioscience) at 1:25 dilution and overnight incu-
bation at 4°C. FOXP3 and PD-1 double staining were
started with a single staining of PD-1 as before, however
after color development with DAB, sections were boiled
for 3 minutes in an antigen retrieval citrate solution (pH
= 6.0) to remove previously attached antibodies. FOXP3
antigen was then stained with mouse anti-FOXP3 anti-
body (236A/E7 clone, ebioscience) diluted at 1:100 for 2
hours at RT followed by goat anti-mouse IgG1 AP (South-
ern Biotech, Birmingham, Alabama, USA) for 30 minutes
at RT. The color for FOXP3 staining was developed with
Fuschin Red (Dako) and sections were counterstained
with instant hematoxylin (Shandon).
Interpretation of stained tumor sections
The B7-H1 and PD-1 staining were scored by an anatom-
ical pathologist (AT) as described previously [18]. FOXP3+
T lymphocytes were scored in 5–10% increments as a per-
centage of total CD3+ staining cells in several high magni-
fication fields. Intratumoral FOXP3+/CD3+ cells were only
considered and counted while intrastromal FOXP3+ cells
were disregarded. FOXP3+ cells with moderate or high
intensity (++ or +++) were considered Tregs while weak
staining (+) were ignored. Due to the co localization of
the CD3 and PD-1 molecules in the T lymphocyte mem-
branes, double staining of PD-1 or B7-H1 and CD3 were
assumed based on single-staining of sequential slides. The
cut off point for positive and negative for FOXP3, B7-H1
and PD-1 was 5% (5% of total CD3+ T-lymphocytes).
Statistical Analysis
Statistical analyses were used to determine the association
between the B7-H1 expression in TIL or FOXP3+ Tregs infil-
tration and the patients' clinico-pathological parameters.
Nominal parameters were analyzed using the fisher exact
test. Comparisons of the independent variables with the
dependent variable were performed using a simple logis-
tic regression analysis. Significance was defined as the
probability of a type one error of < 5%, and 95% confi-
dence intervals were included. The software package SAS
was used for these analyses.
Results
Frequencies of Tregs, B7-H1+ and PD-1+ T lymphocytes in 
normal and breast cancer tissues
In order to determine the frequencies of Tregs, B7-H1 and
PD-1 expressing-T lymphocytes in normal breast tissues
we stained sections obtained from breast patients under-
going plastic surgery (BP) as well as normal breast tissues
adjacent to breast cancer tumors (N) for the expression of
FOXP3, B7-H1 and PD-1 molecules. There were a few T
lymphocytes in both N and BP in which FOXP3+ Tregs rep-
resented <5% of the total CD3+ TIL (Figure 1A). Similarly,
T lymphocytes in normal tissues were negative for B7-H1
(Figure 1B). However, PD-1+ T lymphocytes were abun-
dant in normal tissues with up to 30% of CD3+ cells co-
expressing the PD-1 molecule (Figure 1C). In contrast to
normal breast tissues, 56% of breast cancer patients had a
higher Tregs frequency in their tumor tissues in which
5–50% of CD3+ TILs were Tregs (Figure 1D). Similarly, B7-
H1 was expressed in TILs of 54% of breast cancer patients'
tumor tissues in which 5–80% of TILs express this mole-
cule. B7-H1 expression was not restricted to T lym-
phocytes as 30% of breast cancer patients showed also B7-
H1 expression in their tumor cells (Figure 1E). This result
was also described in our previous study [18]. The PD-1
molecule was expressed in TILs in 60% of the patients in
which 5–70% of TIL express this molecule (Figure 1F).
The expression pattern of the PD-1 molecule was mem-
branous and restricted to T lymphocytes only.
Both intratumoral and intrastromal FOXP3+CD3+ cells
were present in the patients tissues (Figure 2A) and theBMC Cancer 2008, 8:57 http://www.biomedcentral.com/1471-2407/8/57
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expression level of FOXP3 in the intratumoral Tregs ranged
from weak to intense (Figure 2B). Interestingly, most of
FOXP3 intensely stained Tregs were found in close proxim-
ity to tumor cells. PD-1+ T lymphocytes were found both
intrastromal and intratumoral, where they commonly
seen in clumps, or as clumps/single cells respectively.
Correlation of FOXP3, B7-H1 and PD-1 expression in TIL 
with clinicopathological parameters of patients
Breast cancer tissues infiltrated with intratumoral FOXP3+
Tregs  were found to be significantly associated with
patients who had bad prognostic factors such as large
tumor size (P = .029), histological grade III (P < .001),
estrogen receptor negative status (P = .010) and severe
lymphocytic infiltration (P = .051). Intratumoral FOXP3+
Tregs were found also to be associated with progesterone
receptor negative status and lymph node metastasis
although they did not reach statistical significance (Table
1). The correlation of the expression B7-H1 in tumor cells
and FOXP3+ Tregs was also studied. There was a correlation
between B7-H1 in tumor cells and FOXP3+ Tregs (P < .019)
(Table 1).
We have reported previously on the expression of B7-H1
in 50% of 44 breast cancer patients; and found its expres-
sion in TIL to be significantly associated with large tumor
size, high histological grade III, Her2/neu positive status
and severe lymphocytic infiltration [18]. We further exam-
ined the B7-H1 expression in TIL of 62 breast cancer
patients and correlated its expression with the same prog-
nostic factors. Interestingly, very similar correlation was
recorded for B7-H1+ TIL, and this was significantly associ-
ated with high histological grade III (P = .002), estrogen
receptor negative status (P = .029), and sever lymphocytic
infiltration (P = .017). There was also a correlation with
large tumor size with a borderline significance (P = .072)
(Table 1). There was also a correlation between B7-H1 in
tumor cells and B7-H1+ TIL (P  < .002) (Table 1).
Although PD-1 molecule was also expressed by T lym-
phocytes infiltrating normal breast tissues lacking B7-H1,
its presence in tumor tissues is considered essential for the
inhibitory effect of B7-H1 molecule which is abundant in
the tumor tissues. Therefore, we tested whether PD-1 is
concomitantly expressed in the same patients along with
B7-H1+ TIL and FOXP3+ Tregs. We have found that PD-1+
TILs were abundant in patients with high histological
grade III (P = .001), estrogen receptor negative status (P =
.001) and progesterone receptor negative status (P < .001)
(Table 1). There was also a correlation between B7-H1 in
tumor cells and PD-1+ TIL (P < .002) (Table 1).
Immunohistochemical staining of FOXP3+ Tregs B7-H1 +and PD-1+ in T lymphocytes of breast tissues Figure 1
Immunohistochemical staining of FOXP3+ Tregs B7-H1 +and PD-1+ in T lymphocytes of breast tissues. Repre-
sentative micrographs at × 530 magnification of (A&D) CD3/FOXP3 double staining (red color, membranous for CD3 and 
brown nuclear color for FOXP3 expression). (B&E) B7-H1 single staining (brown color, membranous/cytoplasmic expression). 
(C&F) PD-1 single staining (brown color, membranous expression). Upper panel (A-C) is sections for normal breast duct and 
lower panel (D-F) is sections for infiltrating ductal carcinoma of the breast.
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We have found that B7-H1+, PD-1+ TIL and FOXP3+ Tregs
were significantly associated with similar bad prognostic
factors. Therefore, we further investigated the correlation
between B7-H1+ TIL or PD-1+ TIL and FOXP3+ Tregs infil-
tration in breast tumors. There was a highly significant
correlation between the expression of B7-H1 in TIL and
intratumoral FOXP3+ Tregs  (P  < .0001) as shown by
ANOVA test (Figure 3A) and by linear regression analysis
(P < .004 and R2 = 0.3) (Figure 3B). There was also a sig-
nificant correlation between FOXP3+ Tregs infiltration and
PD-1 expression in TIL (P = .007) as shown by ANOVA
(Figure 3C).
Correlation of combined FOXP3, and B7-H1 expression in 
TIL with clinicopathological parameters of patients
We next tested whether a combination of FOXP3 and B7-
H1 molecules will have a synergistic effect on the correla-
tion with the patients' clinicopathological parameters. We
used a combination of the two factors; FOXP3+ Tregs and
B7-H1 expression in TIL in the presence of PD-1 expres-
sion (only patients with B7-H1-expressing TIL were con-
sidered positive when PD-1+ TIL were present in the same
tissue). The combined molecules maintained a significant
correlation with the same prognostic factors (Table 2).
Expression of FOXP3, B7-H1 and PD-1 molecules by 
different subsets of TIL
We next asked whether FOXP3, PD-1 and B7-H1 mole-
cules are expressed by different T lymphocyte subsets.
Double-staining on 6 selected samples which had high
FOXP3+ Tregs, high B7-H1+ TIL and PD-1+ TIL was per-
formed. The selections were based on sections that had a
good morphology to make the interpretation easier. Dou-
ble-staining assays showed that B7-H1 and FOXP3 mole-
cules were generally expressed by different T lymphocyte
subsets (most B7-H1+ TIL were FOXP3- while only very
few FOXP3+ Tregs co-express the B7-H1 molecule). In addi-
tion, the distribution pattern of B7-H1+ TIL was different
from that of FOXP3+ Tregs; Tregs were single cells distributed
over the section of the tumor tissues while B7-H1+ TIL
aggregated in clumps (Figure 4A). Similarly, PD-1 and
FOXP3 molecules were expressed by different T lym-
phocyte subsets (Figure 4B). Furthermore, double stain-
ing assays demonstrated that FOXP3 and CD8 were
Immunohistochemical staining showing intratumoral and intrastromal FOXP3+ Tregs in breast cancer tissues Figure 2
Immunohistochemical staining showing intratumoral and intrastromal FOXP3+ Tregs in breast cancer tissues. 
Representative micrographs at × 530 magnification of CD3+ (red color membranous expression) and FOXP3+ (brown color 
nuclear expression) TIL of (A) intrastromal (left) and intratumoral (right) sections. Solid arrow indicates a CD3+/FOXP3+ Treg 
cell and dashed arrow indicates a CD3+/FOXP3- cell. (B) Intratumoral FOXP3+ TIL with different staining intensity (Intense, 
Medium, and weak). Cells were counterstained with hematoxylin.
Intrastromal Intratumoral
Intense  Medium Weak
A
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mainly expressed by two different T lymphocyte subsets
(Figure 4C) and only very few CD8+ TIL (< 5%) were
FOXP3+. Therefore, it seems that most FOXP3+ Tregs
described here are of the CD4+ subset since they were
restricted to CD3+ T lymphocytes. On the other hand PD-
1 molecule was mainly expressed by CD8+ T lymphocytes
with only few CD8- population were positive for PD-1
(Figure 4D). B7-H1 was mainly expressed by CD8- T lym-
phocytes (Figure 4E) consistent with our previous obser-
vation of its expression by CD4+ T lymphocytes [18].
Table 1: Correlation of FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL with the clinicopathological parameters of 62 breast cancer patients
FOXP3 B7-H1 PD-1
+- * P +- P +-P
Age
< 40 years 15 (68)♣ 7 (32) 1.000 12 (55) 10 (45) 0.595 15 (68) 7 (32) 0.583
≥ 40 years 27 (68) 13 (33) 25 (63) 15 (34) 22 (58) 16 (42)
Tumor Size
<4 CM 18 (55) 15 (45) 0.029 16 (48) 17 (52) 0.072 17 (53) 15 (47) 0.187
≥ 4 CM 24 (83) 5 (17) 21 (72) 8 (28) 20 (71) 8 (29)
Lymph Node Metastasis
Negative 15 (75) 5 (25) 0.107 13 (65) 7 (35) 0.864 12 (63) 7 (37) 0.939
1 to 3 5 (42) 7 (58) 6 (50) 6 (50) 2 (29) 5 (71)
4 to 9 12 (67) 6 (33) 11 (61) 7 (39) 12 (67) 6 (33)
10 or more 9 (90) 1 (10) 6 (60) 4 (40) 5 (56) 4 (44)
Histological Grade (SBR)
II 14 (45) 17 (56) <0.001 12 (39) 19 (61) 0.002 12 (40) 18 (60) 0.001
III 28 (90) 3 (10) 25 (81) 6 (19) 25 (83) 5 (17)
Lymphovascular Invasion
Positive 26 (70) 11 (30) 0.782 25 (68) 12 (32) 0.187 23 (64) 13 (36) 0.787
Negative 16 (64) 9 (36) 12 (48) 13 (52) 14 (58) 10 (42)
Her2/neu status
Positive 13 (62) 8 (38) 0.588 18 (62) 11 (38) 0.798 17 (61) 11 (39) 1.000
Negative 16 (64) 22 (58) 19 (58) 14 (42) 20 (63) 12 (38)
ER status
Positive 24 (57) 18 (43) 0.010 21 (50) 21 (50) 0.029 19 (48) 21 (53) 0.001
Negative 18 (90) 2 (10) 16 (80) 4 (20) 18 (90) 2 (10)
PR status
Positive 17 (57) 13 (43) 0.103 15 (50) 15 (50) 0.195 11 (38) 18 (62) <0.001
Negative 25 (78) 7 (22) 22 (69) 10 (31) 26 (84) 5 (16)
Neo-adjuvant Chemotherapy
With 23 (64) 13 (36) 0.584 20 (56) 16 (44) 0.600 23 (66) 12 (34) 0.591
Without 19 (73) 7 (27) 17 (65) 9 (35) 14 (56) 11 (44)
Lymphocyte Infiltration
Focal 14 (52) 13 (48) 0.051 12 (44) 15 (56) 0.017 12 (46) 14 (54) 0.076
Moderate 14 (74) 5 (26) 11 (58) 8 (42) 13 (68) 6 (32)
Severe 14 (88) 2 (13) 14 (88) 2 (13) 12 (80) 3 (20)
B7-H1 expression of Tumor cells
Positive 17 (89) 2 (11) 0.019 17 (89) 2 (11) 0.002 15 (83) 3 (17) 0.041
Negative 25 (58) 18 (42) 20 (47) 23 (53) 22 (52) 20 (48)
Abbreviations: (+ and -) are number of positive and negative patients, ♣Numbers between brackets are the percentages of patients, Two 
samples had unknown LN+ status, Two samples had unknown PD-1 status *P values in bold represent a significant data.BMC Cancer 2008, 8:57 http://www.biomedcentral.com/1471-2407/8/57
Page 7 of 12
(page number not for citation purposes)
Discussion
The immune system use intricate balance between posi-
tive and negative signals to protect the body from foreign
agents while preventing autoimmunity [33]. This balance
seems to be disturbed in various pathological conditions
resulting in either inhibition of the immune system allow-
ing invasion by tumor cells, or stimulation of the immune
system to cause autoimmune diseases. For example,
although interaction of B7-H1, a coinhibitory molecule,
with its PD-1 ligand is important for prevention of
autoimmunity [34], tumor cells use this interaction as a
mechanism of immune evasion [35]. Furthermore, while
the presence of Tregs is important for suppression of host
immune response to prevent autoimmune diseases [36],
tumor cells can recruit Tregs to inhibit anti-tumor immu-
nity in cancer patients [37].
We have shown previously an abundant expression of B7-
H1 molecule in high-risk breast cancer patients [18] who
have highly proliferative tumor cells [32] and suggested
the involvement of this molecule in the progression of the
disease. In the present report we expanded our study to
investigate the co-involvement of Tregs with B7-H1 in the
immune evasion of breast cancer. Although the interac-
tion between the two types of cells has been demonstrated
in vitro and animal models, their relative infiltration and
correlation with the clinicopathological parameters of
cancer patients have not been well studied. In this study,
we investigated FOXP3+ Tregs and TIL-expressing B7-H1
and its ligand PD-1 in breast cancer patients. We have
used FOXP3 as a detection marker for Tregs as it became
recently a biomarker for studying Tregs  in malignant
human cancers [23]. We have found that FOXP3+ Tregs are
Correlations between FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL Figure 3
Correlations between FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL. (A) statistical analysis of FOXP3+ Tregs infiltration in 
tumor tissues with B7-H1+ TIL, as analyzed with ANOVA of three groups of breast cancer patients with different FOXP3+ Tregs 
infiltration (Low = 0 to 4%, Medium = 5 to 14% and High 15% and above of total CD3+ TIL), (B) their linear correlation analysis 
and (C) statistical analysis of FOXP3+ Tregs infiltration with PD-1+ TIL in breast cancer as analyzed with ANOVA of three 
groups of breast cancer patients with different FOXP3+ Tregs infiltration (Low = 0 to 4%, Medium = 5 to 14% and High 15% and 
above of total CD3+ TIL).
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abundant in tumor tissues of 56% of breast cancer
patients but absent in normal tissues adjacent to the
tumors. FOXP3+  Tregs  infiltrating tumors have been
reported by other studies [25,26,38]. Abundant accumu-
lation of Tregs in tumor tissues might be due to the induc-
tion of CD4+CD25+ Tregs from peripheral CD4+CD25- T
lymphocytes [39,40] and/or migration of Tregs from other
parts of the body to the tumor area by chemotactic factors
like CCL22 [24,41]. This hypothesis is supported by
increase of Tregs in peripheral blood of cancer patients
[25,42].
Standard prognostic factors linked to high-risk breast can-
cer patients include: young age, large tumor size, high his-
tological grade, positive lymph node metastasis and
negative hormonal receptors status [43]. We have demon-
strated that FOXP3+ Tregs infiltrating tumor tissues corre-
lates significantly with important bad prognostic factors:
large tumor size (P = .029), high histological grade (P <
.001) and estrogen receptor negative status (P = .010).
Similar findings have been recently reported by Bates et al
showing an association between high Tregs numbers, and
high histological grade and estrogen receptor negative sta-
tus [26]. Estrogen receptor negative breast tumors are gen-
erally associated with poor prognosis which is usually
attributed to the association with high proliferative rate
and lack of differentiation [44], that are features of pro-
genitors of stem-like cells. Indeed it has been shown
recently that stem cells obtained from both normal and
cancer breast tissues lack the estrogen receptor [45]. Such
stem cells were found to produce TGFβ1 [45] which is
known to induce Tregs [46]. The association of FOXP3+ Tregs
with bad prognostic factors may suggest a contribution of
Tregs infiltrating breast cancer tissues to tumor escape from
the immune system as their depletion lead to tumor rejec-
tion in animal models [47]. We have also confirmed the
B7-H1 expression in TIL and its correlation with bad prog-
nostic factors reported in our previous study [18]. The
association of B7-H1 expression in TIL and FOXP3+ Tregs
infiltration with the same bad prognostic factors suggests
that both molecules correlate with each other. Indeed,
there was a highly significant correlation between the
expression of FOXP3+ Tregs and B7-H1 (P < .0001).
We have also found that PD-1 expression in TIL correlated
with bad prognostic factors. PD-1 has been reported to be
expressed in normal tissues to regulate self-reactive T cell
responses [48]. In the present study PD-1 was expressed in
up to 30% of T lymphocytes from normal breast tissues
while up to 80% of TIL were PD-1+. The abundant expres-
sion of PD-1 in TIL together with B7-H1 (absent in nor-
mal tissues) seen in the present study may contribute to
downregulation of the patients' immune response [4,6].
Furthermore, combination of FOXP3+ Tregs, B7-H1+ TIL
and PD-1+ TIL were found to be highly associated with
patients who had high histological grade III (P < .001)
and estrogen receptor negative tumors (P < .007) sugges-
tive of synergistic contribution to bad prognosis. It seems
Table 2: Correlation between combined FOXP3+ T-reg and B7-
H1 with the clinicopathological parameters of 62 breast cancer 
patients
FOXP3 and B7-H1 Expression *P
Both + One + Both -
Age
< 40 years 21 (55)♣ 7 (18) 10 (26) 0.496
≥ 40 years 10 (45) 7 (32) 5 (23)
Tumor Size
<4 cm 18 (64) 6 (21) 4 (14) 0.128
≥ 4 cm 13 (41) 8 (25) 11 (34)
Lymph Node 
Metastasis
Negative 12 (63) 3 (16) 4 (21) 0.605
1 to 3 4 (33) 3 (25) 5 (42)
4 to 9 9 (50) 5 (28) 4 (22)
10 or more 5 (56) 3 (33) 1 (11)
Histological Grade 
(SBR)
II 9 (30) 7 (23) 14 (47) <0.001
III 22 (73) 7 (23) 1 (3)
Lymphovascular 
Invasion
Positive 20 (56) 8 (22) 8 (2) 0.745
Negative 11 (46) 6 (25) 7 (29)
Her2/neu Status
Positive 16 (57) 7 (25) 5 (18) 0.487
Negative 15 (47) 7 (22) 10 (31)
ER Status
Positive 16 (40) 10 (25) 14 (35) 0.017
Negative 15 (75) 4 (20) 1 (5)
PR Status
Positive 11 (38) 7 (24) 11 (38) 0.054
Negative 20 (65) 7 (23) 4 (13)
Neo-adjuvant 
Chemotherapy
With 17 (49) 9 (26) 9 (26) 0.828
Without 14 (56) 5 (20) 6 (24)
Lymphocyte 
Infiltration
Focal 10 (38) 5 (19) 11 (42) 0.022
Moderate 9 (47) 7 (37) 3 (16)
Severe 12 (80) 2 (13) 1 (7)
Abbreviations: (+ and -) are number of positive and negative 
patients, ♣Numbers between brackets are the percentages of patients, 
Two sample had unknown LN+ status, *P values in bold represent a 
significant data.BMC Cancer 2008, 8:57 http://www.biomedcentral.com/1471-2407/8/57
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that FOXP3, B7-H1 and PD-1 molecules co-expressed in
the TIL of the same tumor tissues may have synergistic
effect in weakening the immune response of patients. IL-
2 may play a fundamental role in regulating the interac-
tion between FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL. B7-
H1/PD-1 interaction contributes to induction of T lym-
phocyte anergy [4] and this can be restored in the presence
of IL-2 [49]. On the other hand, Tregs are dependent on IL-
2 for their expansion and function, and consumption of
IL-2 present in the microenvironment may increase the
inhibitory effect of B7-H1/PD-1 interaction [50].
We also investigated in the present study whether FOXP3,
B7-H1 and PD-1 molecules are expressed by different T
lymphocyte subsets. We have demonstrated that FOXP3+
Tregs is a separate population from PD-1+ and B7-H1+ TIL.
Similar results have been recently reported in non-Hodg-
kin's lymphoma by Yang et al [41] who showed that PD-
1 and B7-H1 expression were mainly found in a subset of
non-Tregs T lymphocytes. The expression of FOXP3 was
confirmed to be linked to CD4+ T lymphocytes as it has
been reported by Roncador et al [51]. We have also con-
firmed our previous findings showing that B7-H1 was
expressed mainly in CD4+ T lymphocytes [18]. On the
other hand, we have shown that PD-1 molecules were
expressed mainly by CD8+ T lymphocytes. It is important
to mention that exhausted CD8+ T lymphocytes have been
reported to express the PD-1 molecule and its blockade
restored the function of these T lymphocytes [52].
One of the most important findings of this study is the co-
localization of immunosuppressive molecules expressed
by different subsets of T lymphocytes in a group of high-
risk breast cancer patients. Indeed, induction of immuno-
suppressive molecules such as B7-H1, PD-1 and Tregs have
been recently shown to counteract the anti-tumor effect of
IL-12-based gene therapy in a transgenic mouse model of
liver cancer [53]. Therefore, current interests in breast can-
cer immunotherapy should be focused on designing
immunological tools to block B7-H1 and its PD-1 ligand
and to deplete Tregs in addition to cancer vaccination [54].
Blocking B7-H1 and PD-1 molecules with monoclonal
antibodies or soluble ligands has been shown to enhance
cancer immunity in animal models [55]. In addition,
elimination of Tregs by an anti-CD25 mAb enhanced anti-
tumor immunity and induced tumor regression in animal
Immunohistochemical staining showing the expression of FOXP3, B7-H1 and PD-1 molecules by different subsets of TIL Figure 4
Immunohistochemical staining showing the expression of FOXP3, B7-H1 and PD-1 molecules by different sub-
sets of TIL. Representative micrographs at × 530 magnification of (A) double staining of B7-H1 (brown color, membranous/
cytoplasmic) and FOXP3 (red color, nuclear) in an area rich in TIL of tumor section. (B) Double staining of PD-1 (brown color, 
membranous) and FOXP3 (red color, nuclear) in sections from the same tumor as in A. (C) double staining of FOXP3 (brown 
color, nuclear) and CD8 (red color, membranous). (D) double staining of PD-1 (brown color, membranous) and CD8 (red 
color, membranous). Solid arrows indicate CD8+/PD-1+ T lymphocytes and dashed arrow indicates a CD8-/PD-1+ T lym-
phocyte. (E) Double staining of B7-H1 (brown color, membranous/cytoplasmic) and CD8 (red color, membranous). Solid 
arrow indicates a CD8+/B7-H1+ T lymphocyte and dashed arrow indicates a CD8-/B7-H1+ T lymphocyte.
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models [47]. Furthermore, elimination of Tregs by IL-2-
conjugated to diphtheria-toxin (ONTAK) enhanced vac-
cine-mediated anti-tumor immunity in cancer patients
[56]. Interestingly, a very recent study, in an animal model
of renal cell carcinoma, has shown that only triple treat-
ment consisting of tumor vaccine, B7-H1 blockade, and
Tregs depletion can result in a complete tumor regression
and long lasting protective immunity [57] supporting the
use of triple therapy treatment of cancer patients.
Conclusion
In conclusion, we have shown a concurrent and abundant
infiltration of different immune suppressive subsets of T
lymphocytes in the microenvironment of high-risk breast
cancer patients. This interesting observation suggests the
development of a new therapeutic modalities aiming at
targeting B7-H1/PD-1 and Tregs in addition to still-devel-
oping immunotherapy.
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